ARTEMISMEDHealthcare

Artemis Medicare Services Limited

Hospital · ISIN INE025R01021 · BSE 542919 · NSE EQ · FV ₹1
Last price
₹300
+5.07%today
What this company does

Artemis Medicare Services Limited operates in Hospital, part of the Healthcare sector. It booked ₹311 cr of revenue in its latest quarter (Q2 FY27) and kept 10.0% of sales as profit.

In the report:
58out of 100
Equitytale Health Score
Mixed

Healthier than 58% of companies in Healthcare, on all six measures of filed financials. Each measure is ranked against the 80–153 companies that reported it.

Measures financial condition, not whether to buy. Learn what this score means · How this is calculated

Price momentum
neutral
RSI (14)
36

At close. Not part of the score.

Profitability & returns48

How much profit it earns on the money it employs

Balance sheet43

How much it owes, and whether earnings cover the interest

Cash quality55

Whether reported profit actually arrives as cash

Growth & consistency83

Whether sales and profit have grown, and how steadily

Valuation47

What today's price implies, against our models or its peers

Governance & risk100

How much of the promoters' stake is pledged, and how much they hold · highest in its sector on what we could measure

Is this company doing well?
not investment advice
Strengths
✓ Makes a profit
✓ Sales up 13% vs last year
✓ Promoters hold 58%
✓ No promoter shares pledged
✓ Turns profit into real cash
Watch-outs
None flagged from our data

What if I invest in ARTEMISMED?

Set a growth rate and see what a monthly SIP would add up to. Your assumption, our arithmetic.

You would put in
₹12.00 lakh
120 instalments
At 0% a year, it would become
₹12.00 lakh

The slider starts at 0%, taken from this company's own free-cash-flow trend. That is history, not a forecast — this is your assumption, and the figure above is arithmetic on it. Returns are not steady year to year, and a real holding would not grow in a straight line. We do not publish price targets or predict returns.

Key ratios · latest quarter + price
₹300▲ +5.07%
latest close · 2026-11-04
1-year return
+739.9%
52-wk low ₹3252-wk high ₹379
Is it cheap or expensive?
What you pay for the profits, book value and cash flow. Higher isn't automatically worse — it can signal faster growth.
P/E ratio38.3High
LowAverageHigh
P/B ratio4.80High
Below bookModerateHigh
EV / EBITDA19.8High
LowAverageHigh
How good is the business?
How much profit it earns from its money and its sales.
Return on equity12.5%Fair
WeakFairStrong ▸15%
Return on capital14.5%Fair
WeakFairStrong
Net margin10.0%Decent
ThinDecentStrong
EBITDA margin20.2%Healthy
ThinDecentHealthy
Is it financially safe?
How much it owes, and whether it can comfortably cover it.
Debt to equity0.24Comfortable
LowModerateHigh ▸1
Interest cover6.5×Strong
RiskyOkayStrong ▸5×
Current ratio1.82Healthy
Tight ◂1HealthyAmple
More figures
Market cap
₹4,753 cr
Book value
₹63
EPS
₹1.96
latest quarter
Net debt
₹223 cr
owes more than its cash
Enterprise value
₹4,976 cr
EBITDA
₹252 cr
annualised
EBIT
₹194 cr
annualised
Operating margin
15.6%
Return on assets
7.8%
Earnings yield
2.61%
P/S
3.82
Sales / share
₹78.6
Tax rate
24.1%
Face value
₹1
Shares
15.8 cr
Working capital
₹214 cr
Current assets
₹477 cr
Current liabilities
₹263 cr
Delivery %
52.9%
Strong / safeFairWeak / riskyValuation — a level, not good/badBands are general rules of thumb, not advice.

P/E, ROE, ROCE and margins are annualised from the latest quarter; per-share and balance-sheet ratios use the most recent balance sheet on file · prices as of 2026-11-04.

Worth vs price · from the FY 2026 report & filings
not investment advice
Hard to value confidentlyLow confidence
The market price is far above what these earnings- and book-based models support — a fast-growing or asset-light business can trade well above them for years, so we won't put a confident number on how overpriced it is.
Models span ₹41–₹79, midpoint ₹60

An educational model from the company's own filings, every assumption shown — not investment advice or a price target. Prices can stay above or below any model for years.

P&L · Q2 FY27 (consolidated)
Revenue from Operations₹311 cr
Other Income₹8 cr
Total Income₹319 cr
Cost of Materials₹64 cr
Purchases of Stock-in-Trade₹0 cr
Employee Benefit Expense₹44 cr
Finance Costs₹7 cr
Depreciation & Amortisation₹14 cr
Other Expenses₹149 cr
Total Expenses₹278 cr
Profit before Tax₹41 cr
Tax Expense₹10 cr
Net Profit₹31 cr
Net margin on total income9.7%
Where the money goes · Q2 FY27
% of total income
Materials + stock-in-trade₹64 cr19.9%
Employee benefit expense₹44 cr13.8%
Finance costs₹7 cr2.3%
Depreciation & amortisation₹14 cr4.5%
Other expenses₹149 cr46.6%
Tax expense₹10 cr3.1%
Profit for the period₹31 cr9.7%
Total income ₹319 cradds up to ₹100 ✓
Quarterly results · consolidated (₹ cr)
MetricQ4 FY26Q1 FY27Q2 FY27
Revenue279 cr287 cr311 cr
Total income287 cr293 cr319 cr
Expenses247 cr250 cr278 cr
Profit before tax40 cr43 cr41 cr
Tax10 cr11 cr10 cr
Net profit (owners' share)30 cr31 cr31 cr
Net margin (owners' share, on revenue)10.8%10.9%10.0%
EPS (₹)1.901.981.96
YoY (latest quarter): total income +13.0% · net profit +3.5%
Balance sheet & cash flow · as of Sep 2026
Low debt
Total assets
₹1,598 cr
Shareholder equity
₹989 cr
parent shareholders
Total debt
₹242 cr
Cash
₹19 cr
Cash flow · H1 FY27
Operating
₹112 cr
Investing
₹-121 cr
Financing
₹-6 cr
Peer comparison
Hospital · by market value
CompanyPriceMarket capP/E
Apollo Hospitals Enterprise Limited₹8,440₹1.21 L cr52.2
Max Healthcare Institute Limited₹896₹87,160 cr52.6
Manipal Health Enterprises Limited₹642₹75,740 cr81.9
Fortis Healthcare Limited₹786₹59,306 cr55.6
Narayana Hrudayalaya Ltd.₹1,871₹38,228 cr31.6
Global Health Limited₹1,326₹35,621 cr40.4
Aster DM Quality Care Limited₹681₹35,303 cr549.5
Krishna Institute of Medical Sciences Limited₹731₹30,681 cr175.6
Dr. Agarwal's Health Care Limited₹513₹16,256 cr89.7
Same industry · latest reported numbers · not a recommendation.
Corporate actions
Dividend yield
0.15%
trailing 12 months
Dividend / share (TTM)
₹0.45
Last dividend
₹0.45
ex 10 Jul 2026
ActionDetailEx-date
Dividend₹0.45 / share10 Jul 2026
Dividend₹0.45 / share11 Jul 2025
Dividend₹0.45 / share5 Jul 2024
Dividend₹0.45 / share14 Jul 2023
Stock splitStock Split From Rs.10/- to Rs.1/-23 Sep 2021
Who owns it · 2026-09-30
No pledge
Promoter
58.4%
FII / Foreign
12.5%
DII / Domestic
1.9%
Retail / others
27.2%
Promoter stake down 9.6% over the last 12 quarters.
Smart-money activity
Insider trades
BoughtNeeru Wahal · Immediate relative1,359 · ₹4.1 L18 Jun 21
BoughtPrem Narain Wahal · Other2,516 · ₹7.6 L18 Jun 21
BoughtPrem Narain Wahal · Other605 · ₹1.8 L17 Jun 21
Bulk / block deals
BoughtMICROCURVES TRADING PRIVATE LIMITED · NSE10.04 L @ ₹365.825 Sep 26
SoldMICROCURVES TRADING PRIVATE LIMITED · NSE10.04 L @ ₹366.1525 Sep 26
Stake changes
BoughtInternational Finance Corporation (IFC)→ 11.98% · 1.90 cr29 Dec 25
BoughtOnkar Kanwar · promoter→ 58.43%15 Nov 25
BoughtInternational Finance Corporation→ 11.99% · 1.90 cr15 Nov 25
Promoter pledges
PledgedInternational Finance Corporation4.12 cr · 0.00% held16 May 24
What shareholders were asked to approve

A company cannot decide everything on its own. Things like a top executive’s pay, issuing new shares, or re-appointing a director have to be put to the people who own the company, and they vote — one vote per share. So whoever owns the most shares has the most say.

Yearly shareholder meeting · 30 Jul 2025
See the official result
1
TO CONSIDER AND ADOPT: A. THE AUDITED STANDALONE FINANCIAL STATEMENT OF THE COMPANY FOR THE FINANCIAL YEAR ENDED MARCH 31, 2025, THE REPORTS OF THE BOARD OF DIRECTORS AND AUDITORS THEREON; AND B. THE AUDITED CONSOLIDATED FINANCIAL STATEMENT OF THE COMPANY FOR THE FINANCIAL YEAR ENDED MARCH 31, 2025 AND REPORT OF AUDITORS THEREON
Backed by 100% of shareholders other than promotersneeded 50%
95.15 L votes for, 49 against · 0% of mutual funds and other big investors said no
2
TO DECLARE THE FINAL DIVIDEND OF RE. 0.45 PER EQUITY SHARE FOR THE FINANCIAL YEAR ENDED MARCH 31, 2025
Backed by 100% of shareholders other than promotersneeded 50%
95.15 L votes for, 9 against · 0% of mutual funds and other big investors said no
3
TO APPOINT A DIRECTOR IN PLACE OF MR. NEERAJ KANWAR (DIN: 00058951), WHO RETIRES BY ROTATION AND BEING ELIGIBLE, OFFERS HIMSELF FOR RE-APPOINTMENT
Backed by 99% of shareholders other than promotersneeded 50%
94.64 L votes for, 51,131 against · 1% of mutual funds and other big investors said no
4
RATIFICATION OF PAYMENT OF REMUNERATION TO COST AUDITORS FOR THE FINANCIAL YEAR 2025-26
Backed by 100% of shareholders other than promotersneeded 50%
95.13 L votes for, 1,852 against · 0% of mutual funds and other big investors said no

Every vote count above is taken from the result the company filed with the stock exchange, certified by an independent counter. To work out what would have happened without the promoters, we simply remove their votes and re-apply the same legal bar the proposal had to clear. Nothing here is an estimate or an opinion.

Who controls this company, and what it pays them

Most Indian companies are controlled by a family or group — the promoters. The exchange requires them to be listed by name, including members who own no shares at all, and requires the company to disclose any business it does with them.

The promoter group — 17 named members
owning 58.4% between them · as of 2026-09-30
Constructive Finance Private Limited58.38%
Onkar Kanwar0.01%
Apollo Tyres Limitedno shares
Classic Industries and Exports Limitedno shares
Fortune Propmart Private Limitedno shares
Indian Institute of Translational Research Private Limitedno shares
Landmark Farms and Housing Private Limitedno shares
Leto Realtors Private Limitedno shares
Business done with them
FY2026 · 3 of the group
The company paid ₹18.1 L to companies in the promoter group last year — about 0.0% of its ₹1,081 cr revenue and received ₹3 cr back from them.
APOLLO TYRES LIMITED.
Provided services to them · Sale of Services/license, Purchase of services/goods
₹3 cr
company received
APOLLO TYRES LIMITED.
Paid them for services · Sale of Services/license, Purchase of services/goods
₹7.1 L
company paid
SHALINI KANWAR CHAND
Other payments to them · Sitting fees
₹6 L
company paid
ONKAR KANWAR
Other payments to them · Sitting fees
also owns 0.01% of the company
₹5 L
company paid

The company also transacted with 21 other related parties — subsidiaries, joint ventures, directors and others — that we could not match by name to the promoter list above. Some may still be connected to the family; we only count the ones the filings let us match with certainty.

Names and holdings from the company’s shareholding pattern filed with the exchange; transactions from the related-party note in its annual report. Every figure is as filed — these are legal, disclosed dealings, and what to make of them is your call.

Money it raised, and what it did with it

When a company raises money from investors, it has to say up front what the money is for. The rules then make it report, every three months until the money is gone, how much of each of those things it has actually paid for — so a promise made while asking for the money can be checked afterwards.

₹330 cr raised in May 2024 by selling shares to selected investors

As of Sep 2026, the company says it has spent 50% of what it set aside, leaving ₹165 cr still to be spent. Care Ratings Limited watches the spending on the exchange’s behalf.

To support acquisition, expansion and capital expenditure requirements of the Company and its subsidiaries (including, by way of investment in its subsidiaries)
49%
₹156 cr of ₹320 cr
Other general corporate purposes
83%
₹8 cr of ₹10 cr
Spent by quarter: 2% → 19% → 19% → 19% → 41% → 47% → 50% (to Sep 2026)

Every figure above is taken from the statement the company files with the stock exchange each quarter, for as long as money it has raised remains unspent. The only thing we work out is how much of each stated purpose has been paid for — one number divided by another from the same filing. Whether a plan that changed was a good change is not something a filing can tell you. See the filing

How the stock has moved · adjusted for splits & bonuses
Data from primary exchange filings · analysis tool, not investment advice.